FR2527444B1 - Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite - Google Patents

Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite

Info

Publication number
FR2527444B1
FR2527444B1 FR8308586A FR8308586A FR2527444B1 FR 2527444 B1 FR2527444 B1 FR 2527444B1 FR 8308586 A FR8308586 A FR 8308586A FR 8308586 A FR8308586 A FR 8308586A FR 2527444 B1 FR2527444 B1 FR 2527444B1
Authority
FR
France
Prior art keywords
refined
toxicity
composition containing
therapeutic composition
endotoxin free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8308586A
Other languages
English (en)
French (fr)
Other versions
FR2527444A1 (fr
Inventor
Edgar Ernst Ribi
John Leonard Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FR2527444A1 publication Critical patent/FR2527444A1/fr
Application granted granted Critical
Publication of FR2527444B1 publication Critical patent/FR2527444B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR8308586A 1982-05-26 1983-05-25 Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite Expired FR2527444B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/382,406 US4435386A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product

Publications (2)

Publication Number Publication Date
FR2527444A1 FR2527444A1 (fr) 1983-12-02
FR2527444B1 true FR2527444B1 (fr) 1987-02-20

Family

ID=23508812

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8308586A Expired FR2527444B1 (fr) 1982-05-26 1983-05-25 Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite

Country Status (7)

Country Link
US (1) US4435386A (cg-RX-API-DMAC7.html)
JP (1) JPS58222027A (cg-RX-API-DMAC7.html)
CA (1) CA1225591A (cg-RX-API-DMAC7.html)
DE (1) DE3318568C2 (cg-RX-API-DMAC7.html)
FR (1) FR2527444B1 (cg-RX-API-DMAC7.html)
GB (1) GB2122084B (cg-RX-API-DMAC7.html)
IT (1) IT1164244B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505899A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
US4497730A (en) * 1984-04-03 1985-02-05 The United States Of America As Represented By The Department Of Health And Human Services Method for obtaining periplasmic proteins from bacterial cells using chloroform
NL8401226A (nl) * 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
US4629722A (en) * 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
WO1998035665A1 (fr) * 1997-02-14 1998-08-20 Ajinomoto Co., Inc. Antagonistes des endotoxines
AU4057300A (en) * 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
JP2013505022A (ja) 2009-09-16 2013-02-14 バクサート インコーポレーティッド Ｈ１ｎ１感染を予防するための免疫戦略の方法
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
BR112016006122B1 (pt) 2013-09-19 2023-11-14 Novavax, Inc COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV)
DK3107568T3 (da) 2014-02-20 2024-06-03 Vaxart Inc Formuleringer til indgivelse til tyndtarmen
EA201792512A1 (ru) 2015-06-12 2018-06-29 Вэксарт, Инк. Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
CA3016457A1 (en) 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
CN109563481B (zh) 2016-07-13 2024-01-05 俄亥俄州创新基金会 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2

Also Published As

Publication number Publication date
GB2122084B (en) 1986-02-05
DE3318568C2 (de) 1987-01-15
CA1225591A (en) 1987-08-18
IT8321289A0 (it) 1983-05-25
FR2527444A1 (fr) 1983-12-02
GB8313054D0 (en) 1983-06-15
GB2122084A (en) 1984-01-11
JPS58222027A (ja) 1983-12-23
JPS6234730B2 (cg-RX-API-DMAC7.html) 1987-07-28
DE3318568A1 (de) 1984-01-12
IT1164244B (it) 1987-04-08
US4435386A (en) 1984-03-06

Similar Documents

Publication Publication Date Title
FR2527444B1 (fr) Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite
FR2527443B1 (fr) Composition contenant de l'endotoxine raffinee et medicament la contenant
EP0719150A4 (en) CELLULAR VACCINE AND METHODS OF USE FOR TREATING MALIGNAS, SOLID TUMORS
IT8027029A0 (it) Complessi platino-diamminici e formulazioni farmaceutiche per il trattamento del cancro che licontengono.
KR970704410A (ko) 암 치료용 종양 세포를 함유하는 이식 장치(Implanted Device Containing Tumor Cells for the Treatment of Cancer)
EP0184040A3 (en) Method and system for removing immunosuppressive components from the blood of mammals
IE830450L (en) Preparation of polysaccharide-protein complexes
FR2406641A1 (fr) 2,6-diaminonebularines et leur application therapeutique
SE8404707D0 (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
IT8323773U1 (it) Mezzi di guida per l'estrazione di cassetti o simili
SE8302519D0 (sv) Solfilterkompositioner
SE8404283L (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
ES2086651T3 (es) Nuevos compuestos, denominados "leustroducsinas", su preparacion y sus utilizaciones terapeuticas.
HU9201197D0 (en) Protection from shock subsequent to injury by double-stranded rns
FR2423223A1 (fr) Vaccin et dose a injecter pour l'immunotherapie d'une maladie neoplasique
IT8121484A0 (it) Estratto da piante del genere epimedium, procedimento per lapreparazione di detto estratto, agente immunostimolante che comprende detto estratto come componente efficace e immunoterapia mediante l'impiego di detto estratto.
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
FR2429212A1 (fr) Derives de phenylpiperazine et leur application en therapeutique
IT1189224B (it) Sostanze carcinostatiche ed immunostimolanti tf-2,procedimento per prepararle ed agente carcinostatico che le contiene
Lam et al. Effect of local tumor irradiation and interleukin-2 therapy in different murine tumors
FR2316964A1 (fr) Medicament contenant, a titre de principe actif, un produit a base de polysaccharides, notamment obtenu a partir de lipopolysaccharides bacteriens
NL7701991A (nl) Werkwijze voor de behandeling van spijsverte- ringsorgaankankers en de fiber-scoop injektor daarvoor voor bioptische doeleinden.
IT1224673B (it) Composizione farmaceutica comprendente un analogo di somatostatina esuo impiego nel trattamento del cancro della mammella

Legal Events

Date Code Title Description
ER Errata listed in the french official journal (bopi)

Free format text: 48/83

ST Notification of lapse